Literature DB >> 26077392

Local Synthesis of Pepsin in Barrett's Esophagus and the Role of Pepsin in Esophageal Adenocarcinoma.

Tina Samuels1, Craig Hoekzema1, Jon Gould2, Matthew Goldblatt2, Matthew Frelich2, Matthew Bosler2, Sang-Hyuk Lee3, Nikki Johnston4.   

Abstract

OBJECTIVE: Despite widespread use of proton pump inhibitors (PPIs), the incidence of esophageal adenocarcinoma (EAC) continues to rise. PPIs reduce reflux acidity, but only transiently inactivate gastric enzymes. Nonacid reflux, specifically nonacid pepsin, contributes to carcinogenesis in the larynx. Given the carcinogenic potential of pepsin and inefficacy of PPIs to prevent EAC, the presence and effect of pepsin in the esophagus should be investigated.
METHODS: Normal and Barrett's biopsies from 8 Barrett's esophagus patients were collected for pepsin analysis via Western blot and reverse transcriptase-polymerase chain reaction (RT-PCR). Human esophageal cells cultured from healthy patients were treated with pepsin (0.01-1 mg/mL; 1-20 hours), acid (pH 4)±pepsin (5 minutes); real-time RT-PCR, ELISA, and cell migration were assayed.
RESULTS: Pepsin was detected in all 8 Barrett's and 4 of 8 adjacent normal specimens. Pepsinogen mRNA was observed in 22 Barrett's, but not in normal adjacent samples. Pepsin induced PTSG2 (COX-2) and IL-1β expression and cell migration in vitro.
CONCLUSIONS: Pepsin is synthesized by metaplastic, Barrett's esophageal mucosa. Nonacid pepsin increases metrics of tumorigenicity in esophageal epithelial cells in vitro. These findings implicate refluxed and locally synthesized pepsin in development and progression of EAC and, in part, explain the inefficacy of PPIs in the prevention of EAC.
© The Author(s) 2015.

Entities:  

Keywords:  Barrett’s esophagus; adenocarcinoma of esophagus; gastroesophageal reflux; pepsin; proton pump inhibitors; reflux

Mesh:

Substances:

Year:  2015        PMID: 26077392      PMCID: PMC4750403          DOI: 10.1177/0003489415590657

Source DB:  PubMed          Journal:  Ann Otol Rhinol Laryngol        ISSN: 0003-4894            Impact factor:   1.547


  33 in total

1.  Cell biology of laryngeal epithelial defenses in health and disease: preliminary studies.

Authors:  S E Axford; N Sharp; P E Ross; J P Pearson; P W Dettmar; M Panetti; J A Koufman
Journal:  Ann Otol Rhinol Laryngol       Date:  2001-12       Impact factor: 1.547

2.  Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole.

Authors:  M F Vela; L Camacho-Lobato; R Srinivasan; R Tutuian; P O Katz; D O Castell
Journal:  Gastroenterology       Date:  2001-06       Impact factor: 22.682

3.  Antireflux surgery for dysplastic Barrett's esophagus.

Authors:  John G Hunter
Journal:  World J Surg       Date:  2015-03       Impact factor: 3.352

4.  Differential expression of pepsinogen isozymogens in a patient with Barrett esophagus.

Authors:  G Pals; A W Eriksson; J C Pronk; R R Frants; E C Klinkenberg-Knol; A Bosma; B D Westerveld; R T Taggart; I M Samloff; S G Meuwissen
Journal:  Clin Genet       Date:  1988-08       Impact factor: 4.438

Review 5.  Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systematic review.

Authors:  Gareth S Dulai; Sushovan Guha; Katherine L Kahn; Jeffrey Gornbein; Wilfred M Weinstein
Journal:  Gastroenterology       Date:  2002-01       Impact factor: 22.682

6.  Inflammatory gradient in Barrett's oesophagus: implications for disease complications.

Authors:  R C Fitzgerald; S Abdalla; B A Onwuegbusi; P Sirieix; I T Saeed; W R Burnham; M J G Farthing
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

7.  Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus.

Authors:  Baljeet S Kaur; Niloufar Khamnehei; Mohamed Iravani; Sai S Namburu; Otto Lin; George Triadafilopoulos
Journal:  Gastroenterology       Date:  2002-07       Impact factor: 22.682

Review 8.  Epidemiology of esophageal cancer.

Authors:  Yuwei Zhang
Journal:  World J Gastroenterol       Date:  2013-09-14       Impact factor: 5.742

9.  Pepsin promotes proliferation of laryngeal and pharyngeal epithelial cells.

Authors:  Nikki Johnston; Justin C Yan; Craig R Hoekzema; Tina L Samuels; Gary D Stoner; Joel H Blumin; Jonathan M Bock
Journal:  Laryngoscope       Date:  2012-05-08       Impact factor: 3.325

Review 10.  Systematic review and meta-analysis of tumor biomarkers in predicting prognosis in esophageal cancer.

Authors:  Meilan Chen; Jizheng Huang; Zhenli Zhu; Jun Zhang; Ke Li
Journal:  BMC Cancer       Date:  2013-11-11       Impact factor: 4.430

View more
  3 in total

1.  Pepsin promotes IL-8 signaling-induced epithelial-mesenchymal transition in laryngeal carcinoma.

Authors:  Jia-Jie Tan; Lu Wang; Ting-Ting Mo; Jie Wang; Mei-Gui Wang; Xiang-Ping Li
Journal:  Cancer Cell Int       Date:  2019-03-20       Impact factor: 5.722

2.  Trends in gastroesophageal reflux disease research: A bibliometric and visualized study.

Authors:  Tai Zhang; Beihua Zhang; Wende Tian; Yuchen Wei; Fengyun Wang; Xiaolan Yin; Xiuxiu Wei; Jiali Liu; Xudong Tang
Journal:  Front Med (Lausanne)       Date:  2022-09-29

Review 3.  Pepsin and Laryngeal and Hypopharyngeal Carcinomas.

Authors:  Cheng-Yi Yin; Sha-Sha Zhang; Jiang-Tao Zhong; Shui-Hong Zhou
Journal:  Clin Exp Otorhinolaryngol       Date:  2020-07-24       Impact factor: 3.372

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.